Our robust clinical research program and transformative science is helping to drive improved long-term outcomes for people living with cancer,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. “Research at this year’s ESMO reinforces the depth and breadth of our development program, spanning from earlier to late stages of cancer. Presentations will include data across our oncology portfolio, such as data that support the role of Opdivo-based approaches in earlier stages of cancer, reinforce the durable long-term survival and health-related quality of life benefits of Opdivo-based combinations, and further demonstrate the benefit of LAG-3 blocking antibody combinations in melanoma with Opdualag. Over 90 Bristol Myers Squibb-sponsored studies, investigator-sponsored studies, and collaborations will be presented at the Congress. PRINCETON, N.J.-(BUSINESS WIRE)- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology (ESMO) Congress 2022 from September 9-13 in Paris, France. Response outcomes data continue to build upon the clinical evidence of Opdualag (nivolumab and relatlimab-rmbw) in advanced melanomaĮxploratory analyses in non-small cell lung cancer and urothelial carcinoma support the potential benefit of immunotherapy in earlier stages of cancer Long-term data continue to reinforce benefits of Opdivo (nivolumab)-based combinations
0 kommentar(er)
